"Most countries around Europe will be following the German lead," writes Mike Sassano, CEO of Somai Pharmaceuticals.
The appointment will be made following suspension of the company’s shares from the AQSE.
The acquisition is a cornerstone of Halo’s shareholder value enhancement strategy, says CEO.
A new report projects sales for unlicensed medical cannabis in Europe.
Canaccord Genuity was advised on Summerway Capital Plc’s AIM listing.
Kanabo surprised the market with its £14m acquisition of the GP Service - so, what does this mean for the UK industry and patients?
The financing will support Halo Collective's US west coast expansion strategy.
The company will trade under the ticker AKAN.
The appeal states there is an urgent need to address serious governance and sclerotic management issues.
Cannabis Wealth speaks to Rob Koch, director of strategy and information at California distributor, Nabis.